A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients
Authors:
Open Access
- 2 July 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (7) , e2565
Abstract
The safety of the immune complexes composed of yeast-derived hepatitis B surface antigen (HBsAg) and antibodies (abbreviated as YIC) among healthy adults and chronic hepatitis B patients has been proved in phase I and phase IIa trial. A larger number of patients for study of dosage and efficacy are therefore needed. Two hundred forty two HBeAg-positive chronic hepatitis B patients were immunized with six injections of either 30 µg YIC, 60 µg of YIC or alum adjuvant as placebo at four-week intervals under code. HBV markers and HBV DNA were monitored during immunization and 24 weeks after the completion of immunization. The primary endpoint was defined as loss of HBeAg, or presence of anti-HBe antibody or suppression of HBV DNA, while the secondary endpoint was both HBeAg seroconversion and suppression of HBV DNA. Statistical significance was not reached in primary endpoints four weeks after the end of treatment among three groups, however, at the end of follow-up, HBeAg sero-conversion rate was 21.8%(17/78) and 9% (7/78) in the 60 µg YIC and placebo groups respectively (p = 0.03), with 95% confidence intervals at 1.5% to 24.1%. Using generalized estimating equations (GEEs) model, a significant difference of group effects was found between 60 µg YIC and the placebo groups in terms of the primary endpoint. Eleven serious adverse events occurred, which were 5.1%, 3.6%, and 5.0% in the placebo, 30 µg YIC and 60 µg YIC groups respectively (p>0.05). Though statistical differences in the preset primary and secondary endpoints among the three groups were not reached, a late and promising HBeAg seroconversion effect was shown in the 60 µg YIC immunized regimen. By increasing the number of patients and injections, the therapeutic efficacy of YIC in chronic hepatitis B patients will be further evaluated. ChiCTR.org ChiCTR-TRC-00000022Keywords
This publication has 30 references indexed in Scilit:
- Immunology of hepatitis B virus and hepatitis C virus infectionNature Reviews Immunology, 2005
- Immunomodulatory therapy for chronic hepatitis B virus infectionFundamental & Clinical Pharmacology, 2004
- Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteersHepatology Research, 2004
- Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell PopulationScience, 2004
- Selective functional deficit in dendritic cell – T cell interaction is a crucial mechanism in chronic hepatitis B virus infectionJournal of Viral Hepatitis, 2004
- Dna Prime/Canarypox Boost—Based Immunotherapy of Chronic Hepatitis B Virus Infection in A ChimpanzeeHepatology, 2001
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995
- Specific vaccine therapy in chronic hepatitis B infectionThe Lancet, 1994
- Vaccines Get a New TwistScience, 1994
- Immunization with Solid Matrix-Antibody-Antigen Complexes Containing Surface or Internal Virus Structural Proteins Protects Mice from Infection with the Paramyxovirus, Simian Virus 5Journal of General Virology, 1988